Diasorin S.p.a. · MIL:DIA
Diasorin — Q1 2025 Earnings Presentation
18 slides from Diasorin's earnings presentation, May 6, 2025
Slide 1: Q1 2025 Results
>) Oiasorin Q1 2025 RESULTS May 6, 2025 }) Diasorin
Slide 2: Disclaimer
DISCLAIMER In General. This disclaimer applies to this presentation and any oral No distribution of this Presentation. This Presentation is being furnished to you comments of any person presenting it. This document, taken together with solely for your information and may not be reproduced, in whole
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 5: Financial Highlights
FINANCIAL HIGHLIGHTS Change Amounts in millions of euros Q1 2025 @ current @ CER Revenues 313 +8% +7% Immunodiagnostics ex-COVID 203 +9% +8% Molecular Diagnostics ex-COVID 56 +10% +7% Licensed Technologies 50 +16% +13% COVID 5 -48% -48% Revenues ex-COVID 309 +10% +9% Adjusted1 EBITDA2 107 +10% +10%
Slide 6: Q1 2025 Key Facts
Q1 2025 KEY FACTS PRODUCT & BUSINESS DEVELOPMENT MOLECULAR DIAGNOSTICS TARGETED • Launch of the Simplexa® C. auris Direct assay for the LIAISON® MDX platform on all countries accepting the CE Mark MULTIPLEX • FDA 510(k) clearance of the LIAISON PLEX® Gram-Negative Blood Culture Assay, the second Blo
Slide 7: Managerial Outlook on Q1'25 Revenues
MANAGERIAL OUTLOOK ON Q1’25 REVENUES Q1 2025 Group revenues (data in €/mln) Data @CUR Data @CER +8% +7% +10% ex-COVID 313 +9% ex-COVID 309 289 289 5 5 COVID sales 9 50 9 48 43 43 56 55 Licensed Technologies 51 51 Molecular Diagnostics ex-COVID 186 203 186 201 Immunodiagnostics ex-COVID Q1’24 Q1’25 Q
Slide 8: Q1'25 Revenues by Geography
Q1’25 REVENUES BY GEOGRAPHY (data @ current exchange rates) Q1’24 Q1’25 Rest of the World Rest of the World 15% 14% North America North America Direct Direct 49% 52% Europe Direct Europe Direct 34% 36% 8
Slide 9: Q1'25 Profitability Profile
Q1’25 PROFITABILITY PROFILE (data in €/mln @ current exchange rates) 34% 34% 313 Q1’25 Adjusted1 EBITDA2 is better than last year by €/mln 10 or 289 Net Revenues +10%, whereas Adjusted1 EBITDA2 Margin is in line with the previous year and consistent with the guidance, mainly as a result Adjusted1 EB
Slide 10: FY 2025 Company Guidance
FY 2025 COMPANY GUIDANCE
Slide 11: FY'25 Guidance Confirmed
FY’25 GUIDANCE CONFIRMED FY’25 GUIDANCE (@CER 2024) Ex-COVID revenues: approx. +8%, approx. +7% including COVID revenues (equal to approx. 20 €/mln) Adjusted1 EBITDA2 Margin: approx. 34% 1 With reference to the Adjusted EBITDA, Adjusted EBIT and Adjusted Net Profit indicators, please refer to the ta
Slide 12: Financial Schemes
FINANCIAL SCHEMES
Slide 13: Income Statement
INCOME STATEMENT 2 EBITDA is defined as the “Operating Result”, gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefor
Slide 14: Balance Sheet
Amounts in millions of euros Goodwill and intangibles assets Property, plant and equipment Other non-current assets Net working capital Other non-current liabilities Net Invested Capital Net Financial Debt Total shareholders’ equity }) Diasorin BALANCE SHEET 12/31/2024 03/31/2025 2,028 1,951 -78 2n
Slide 15: Cash Flow Statement
CASH FLOW STATEMENT Amounts in millions of euros Cash and cash equivalents at the beginning of the period Cash provided by operating activities Cash provided/(used) in investing a ies Cash provided/(used) in financing activities Net change in cash and cash equivalents before investments in financial
Slide 16: Q1'25 Reconciliation to Consolidated Financial Statements
Q1’25 RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS Amounts in millions of euros Gross Profit EBITDA EBIT Net Result IFRS Financial Statements Measures 205 106 73 52 % on Revenues 65% 34% 23% 17% Adjustments “One-off” costs related to the integration and restructuring of Luminex - 0 0 0 Deprec
Slide 17: Q1'24 Reconciliation to Consolidated Financial Statements
Q1’24 RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS Amounts in millions of euros Gross Profit EBITDA EBIT Net Result IFRS Financial Statements Measures 191 96 63 46 % on Revenues 66% 33% 22% 16% Adjustments “One-off” costs related to the integration and restructuring of Luminex - 1 1 1 Depreci
Slide 18: }) Diasorin
}) Diasorin